A-protein Levels in Adult and Pediatric Brain Tumor Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00165542|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : November 23, 2016
|Condition or disease||Intervention/treatment|
|Malignant Childhood Central Nervous System Neoplasm||Other: A PROTEIN level|
- Patients will be identified at the time of presentation to their neurologist, neurosurgeon or oncologist.
- Blood or cerebrospinal fluid will be collected for this study only when they are being collected for other reasons before and after each surgery. Samples will also be collected after any event such as significant change in symptoms or radiographic progression.
- Once the patients condition has been stabilized, samples will be take at regular intervals of >= 1 month. The duration of this study is 24 months.
|Study Type :||Observational|
|Actual Enrollment :||54 participants|
|Official Title:||Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients|
|Study Start Date :||June 1998|
|Actual Primary Completion Date :||February 2004|
|Actual Study Completion Date :||August 2009|
A PROTEIN levels in all patients and with all tumor types.
Other: A PROTEIN level
- association between serum A-Protein level class and clinical status [ Time Frame: 4 years ]Serum samples were collected when patients were due for clinically indicated phlebotomy. Serum A-PROTEIN levels were determined using a competitive labeled antibody assay and patients were classified into 3 groups: negative <7pM, equivocal 7-9.9 pM and positive >/= 10 pM; Clinical status at the same time of the sample collection was established by MRI scans and patients grouped as either resected/decreased versus stable/increased. The relationship between clinical status and A-PROTEIN level was assessed using general estimating equations. Association was defined as a statistically significant p-value from the regression model.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165542
|United States, Massachusetts|
|Dana Farber Cancer Institite|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Mark W Kieran, MD,PhD||Dana-Farber Cancer Institute|